ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Diagnosed with advanced ovarian cancer? Learn why HRD testing may help guide your care.

(BPT) - A diagnosis of advanced ovarian cancer can feel overwhelming, emotionally, physically and mentally. There are many decisions to make, and one empowering way to take control is to understand as much as possible about your specific tumor.

For people diagnosed with advanced ovarian cancer, this means knowing your tumor's HRD status, which can help your health care team treat your specific type of cancer.1 The more information your doctors have, the better equipped they are to recommend a treatment plan that fits you.

Understanding HRD

HRD stands for homologous recombination deficiency, a term that refers to a tumor's inability to repair certain types of DNA damage, which impacts how cancer cells grow, die and respond to different treatments.2 About 50% of people with advanced ovarian cancer have tumors that are HRD-positive, which is why testing can be so important.2

To find out your HRD status, doctors may recommend a tumor test, also known as a genomic or biomarker test.3 This type of test looks at the DNA in your tumor to detect both inherited and acquired mutations.3 It can identify changes that may influence how your cancer grows or responds to treatment.1

This is different from genetic testing, which looks at inherited genes in your DNA (such as BRCA1 or BRCA2). Genetic tests can help identify the potential for developing certain diseases, including some cancers.3

The Importance of HRD Testing

When doctors understand more about a tumor's biology, including biomarkers like HRD, they can tailor treatments more precisely. This approach, called precision or personalized medicine, helps match you with therapies that are most likely to be effective for your specific type of cancer and avoid those that are less likely to help.3

Treatment options for advanced ovarian cancer could depend on the results of your HRD status and may include surgery, chemotherapy or targeted therapies.4

How Do I Get Tested?

The first step is simple: talk to your doctor about HRD testing. It usually requires a tissue sample from a tumor, which may be collected during surgery or a biopsy.1 Your health care team can explain the process and what your results might mean for your treatment.

Support To Help You Feel Informed

When you understand your cancer more fully, you may feel more equipped to ask questions, make decisions and share what matters most to you. That kind of clarity can help you feel supported and heard throughout your journey.

To help you get started, TestForHRD.com offers trusted resources, including:

  • A Doctor Discussion Guide to support conversations with your care team
  • An FAQ section based on common patient experiences
  • Additional insights and tools to help you feel more confident and less alone

Take the next step in understanding your diagnosis. Visit TestForHRD.com for information and support.

References:

1 Medical News Today. What to know about HRD testing for ovarian cancer. Accessed July 16, 2025. https://www.medicalnewstoday.com/articles/hrd-positive-ovarian-cancer.

2 AstraZeneca Precision Medicine. HRD in Advanced Ovarian Cancer. Accessed July 16, 2025. https://www.azprecisionmed.com/ovarian-cancer/hrd-testing.

3 National Cancer Institute. Biomarker testing for cancer treatment. Accessed July 16, 2025. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment.

4 Centers for Disease Control and Prevention. Treatment of Ovarian Cancer. Accessed July 16, 2025. https://www.cdc.gov/ovarian-cancer/treatment/index.html.

US-103453 Last Updated 7/25

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.